Abstract
AbstractThis retrospective cohort study aimed to assess whether basal septal wall thickness (BSWT), anterior (AML) and posterior (PML) mitral leaflet length, or sex were associated with remaining left ventricular outflow tract obstruction (LVOTO) in patients with hypertrophic obstructive cardiomyopathy (HOCM) undergoing alcohol septal ablation (ASA). One hundred fifty-four patients who underwent ASA at the Karolinska University Hospital in Stockholm, Sweden, between 2009 and 2021, were included retrospectively. Anatomical and hemodynamic parameters were collected from invasive catheterization before and during ASA, and from echocardiography (ECHO) examinations before, during, and at 1-year follow-up after ASA. Linear and logistic regression models were used to assess the association between sex, BSWT, AML, PML, and outcome, which was defined as the remaining LVOTO (≥ 30 mmHg) after ASA. The median follow-up was 364 days (interquartile range 334–385 days). BSWT ≥ 23 mm (n = 13, 12%) was associated with remaining LVOTO at follow-up (p = 0.004). Elongated mitral valve leaflet length (either AML or PML) was present in 125 (90%) patients. Elongated AML (> 24 mm) was present in 67 (44%) patients, although AML length was not associated with remaining LVOTO at follow-up. Elongated PML (> 14 mm) was present in 114 (74%) patients and was not associated with remaining LVOTO at follow-up. No significant sex differences were observed regarding the remaining LVOTO. ECHO measurement of BSWT can be effectively used to select patients for successful ASA and identify those patients with a risk of incomplete resolution of LVOTO after ASA.
Graphical abstract
Funder
Swedish Heart-Lung foundation
European Union
Hjärt-Lungfonden
Karolinska Institute
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–626. https://doi.org/10.1093/eurheartj/ehad194.
2. Guigui SA, Torres C, Escolar E, Mihos CG. Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review. J Thorac Dis. 2022;14(6):2309–25. https://doi.org/10.21037/jtd-22-182.
3. Lentz Carvalho J, Schaff HV, Nishimura RA, Ommen SR, Geske JB, Lahr BD, et al. Is anterior mitral valve leaflet length important in outcome of septal myectomy for obstructive hypertrophic cardiomyopathy? J Thorac Cardiovasc Surg. 2023;165(1):79-87.e1. https://doi.org/10.1016/j.jtcvs.2020.12.143.
4. Spaziano M, Sawaya FJ, Lefèvre T. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: indications, technical aspects, and clinical outcomes. J Invasive Cardiol. 2017;29(12):404–10.
5. Dahal R, Siddiqui T, Adnan G. Catheter management of hypertrophic cardiomyopathy. StatPearls Publishing; 2022 [cited 2023 11 Oct]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK570640/. Accessed 11 Oct 2023.